Reviews Tobramycin


No reviews yet.

Tobramycin Injection Drug Description
Tobramycin
for Injection USP 1.2 gm†
This vial is intended for use by the hospital pharmacist in the extemporaneous
preparation of IV solutions.

PHARMACY BULK PACKAGE NOT FOR DIRECT INFUSION

To reduce the development of drug-resistant bacteria and maintain the effectiveness
of Tobramycin for Injection USP and other antibacterial drugs, tobramycin should
be used only to treat or prevent infections that are proven or strongly suspected
to be caused by bacteria.

WARNING
Patients treated with tobramycin for injection USP and other aminoglycosides
should be under close clinical observation, because these drugs have an inherent
potential for causing ototoxicity and nephrotoxicity. Neurotoxicity, manifested
as both auditory and vestibular ototoxicity, can occur. The auditory changes
are irreversible, are usually bilateral, and may be partial or total. Eighth-nerve
impairment and nephrotoxicity may develop, primarily in patients having preexisting
renal damage and in those with normal renal function to whom aminoglycosides
are administered for longer periods or in higher doses than those recommended.
Other manifestations of neurotoxicity may include numbness, skin tingling, muscle
twitching, and convulsions. The risk of aminoglycoside-induced hearing loss
increases with the degree of exposure to either high peak or high trough serum
concentrations. Patients who develop cochlear damage may not have symptoms during
therapy to warn them of eighth-nerve toxicity, and partial or total irreversible
bilateral deafness may continue to develop after the drug has been discontinued.
Rarely, nephrotoxicity may become apparent until the first few days after cessation
of therapy. Aminoglycoside-induced nephrotoxicity usually is reversible.
Renal and eighth-nerve function should be closely monitored in patients with
known or suspected renal impairment and also in those whose renal function is
initially normal but who develop signs of renal dysfunction during therapy.
Peak and trough serum concentrations of aminoglycosides should be monitored
periodically during therapy to assure adequate levels and to avoid potentially
toxic levels. Prolonged serum concentrations above 12 mcg/mL should be avoided.
Rising trough levels (above 2 mcg/mL) may indicate tissue accumulation. Such
accumulation, excessive peak concentrations, advanced age, and cumulative dose
may contribute to ototoxicity and nephrotoxicity (see PRECAUTIONS).
Urine should be examined for decreased specific gravity and increased excretion
of protein, cells, and casts. Blood urea nitrogen, serum creatinine, and creatinine
clearance should be measured periodically. When feasible, it is recommended
that serial audiograms be obtained in patients old enough to be tested, particularly
high-risk patients. Evidence of impairment of renal, vestibular, or auditory
function requires discontinuation of the drug or dosage adjustment.
Tobramycin for injection USP should be used with caution in premature and neonatal
infants because of their renal immaturity and the resulting prolongation of
serum half-life of the drug.
Concurrent and sequential use of other neurotoxic and/or nephrotoxic antibiotics,
particularly other aminoglycosides (eg. amikacin, streptomycin, neomycin, kanamycin,
gentamicin, and paromomycin), cephaloridine, viomycin, polymycin B, colistin,
cisplatin, and vancomycin, should be avoided. Other factors that may increase
patient risk are advanced age and dehydration.
Aminoglycosides should not be given concurrently with potent diuretics, such
as ethacrynic acid and furosemide. Some diuretics themselves cause ototoxicity,
and intravenously administered diuretics enhance aminoglycoside toxicity by
altering antibiotic concentrations in serum and tissue.
Aminoglycosides can cause fetal harm when administered to a pregnant woman
(see PRECAUTIONS).

DRUG DESCRIPTION
Tobramycin sulfate, a water-soluble antibiotic of the aminoglycoside group,
is derived from the actinomycete Streptomyces tenebrarius. Sterile tobramycin
sulfate is supplied as a sterile dry powder and is intended for reconstitution
with 30 mL of Sterile Water for Injection, USP. Sulfuric acid and/or sodium
hydroxide may have been added during manufacture to adjust the pH. †
Each vial contains tobramycin sulfate equivalent to 1200 mg of tobramycin. After
reconstitution, the solution will contain 40 mg of tobramycin per mL. The product
contains no preservative or sodium bisulfite.
Tobramycin sulfate is 0-3-amino-3-deoxy-a-D-glucopyranosyl-(1→4)-
0-[2,6-diamino-2,3,6-trideoxy-a-D-ribo-hexopyranosyl-(1→6)]-2-deoxy-
L-streptamine, sulfate (2:5)(salt) and has the chemical formula (C18H37N5O9)2•5H2SO4.
The molecular weight is 1425.45. The structural formula for tobramycin is as
follows:








The pharmacy bulk package of tobramycin for injection USP is a container of
a sterile preparation for parenteral use that contains multiple single doses.
It is intended for use in a pharmacy admixture program. Package use is restricted
to the preparation of admixures for intravenous infusion or to the filling of
empty sterile syringes for intravenous injections for patients with individualized
dosing requirements.
† Each vial contains tobramycin sulfate equivalent to
1200 mg of tobramycin.
Last reviewed on RxList: 11/13/2008




Tobramycin Injection Drug Description
Tobramycin
for Injection USP 1.2 gm†
This vial is intended for use by the hospital pharmacist in the extemporaneous
preparation of IV solutions.

PHARMACY BULK PACKAGE NOT FOR DIRECT INFUSION

To reduce the development of drug-resistant bacteria and maintain the effectiveness
of Tobramycin for Injection USP and other antibacterial drugs, tobramycin should
be used only to treat or prevent infections that are proven or strongly suspected
to be caused by bacteria.

WARNING
Patients treated with tobramycin for injection USP and other aminoglycosides
should be under close clinical observation, because these drugs have an inherent
potential for causing ototoxicity and nephrotoxicity. Neurotoxicity, manifested
as both auditory and vestibular ototoxicity, can occur. The auditory changes
are irreversible, are usually bilateral, and may be partial or total. Eighth-nerve
impairment and nephrotoxicity may develop, primarily in patients having preexisting
renal damage and in those with normal renal function to whom aminoglycosides
are administered for longer periods or in higher doses than those recommended.
Other manifestations of neurotoxicity may include numbness, skin tingling, muscle
twitching, and convulsions. The risk of aminoglycoside-induced hearing loss
increases with the degree of exposure to either high peak or high trough serum
concentrations. Patients who develop cochlear damage may not have symptoms during
therapy to warn them of eighth-nerve toxicity, and partial or total irreversible
bilateral deafness may continue to develop after the drug has been discontinued.
Rarely, nephrotoxicity may become apparent until the first few days after cessation
of therapy. Aminoglycoside-induced nephrotoxicity usually is reversible.
Renal and eighth-nerve function should be closely monitored in patients with
known or suspected renal impairment and also in those whose renal function is
initially normal but who develop signs of renal dysfunction during therapy.
Peak and trough serum concentrations of aminoglycosides should be monitored
periodically during therapy to assure adequate levels and to avoid potentially
toxic levels. Prolonged serum concentrations above 12 mcg/mL should be avoided.
Rising trough levels (above 2 mcg/mL) may indicate tissue accumulation. Such
accumulation, excessive peak concentrations, advanced age, and cumulative dose
may contribute to ototoxicity and nephrotoxicity (see PRECAUTIONS).
Urine should be examined for decreased specific gravity and increased excretion
of protein, cells, and casts. Blood urea nitrogen, serum creatinine, and creatinine
clearance should be measured periodically. When feasible, it is recommended
that serial audiograms be obtained in patients old enough to be tested, particularly
high-risk patients. Evidence of impairment of renal, vestibular, or auditory
function requires discontinuation of the drug or dosage adjustment.
Tobramycin for injection USP should be used with caution in premature and neonatal
infants because of their renal immaturity and the resulting prolongation of
serum half-life of the drug.
Concurrent and sequential use of other neurotoxic and/or nephrotoxic antibiotics,
particularly other aminoglycosides (eg. amikacin, streptomycin, neomycin, kanamycin,
gentamicin, and paromomycin), cephaloridine, viomycin, polymycin B, colistin,
cisplatin, and vancomycin, should be avoided. Other factors that may increase
patient risk are advanced age and dehydration.
Aminoglycosides should not be given concurrently with potent diuretics, such
as ethacrynic acid and furosemide. Some diuretics themselves cause ototoxicity,
and intravenously administered diuretics enhance aminoglycoside toxicity by
altering antibiotic concentrations in serum and tissue.
Aminoglycosides can cause fetal harm when administered to a pregnant woman
(see PRECAUTIONS).

DRUG DESCRIPTION
Tobramycin sulfate, a water-soluble antibiotic of the aminoglycoside group,
is derived from the actinomycete Streptomyces tenebrarius. Sterile tobramycin
sulfate is supplied as a sterile dry powder and is intended for reconstitution
with 30 mL of Sterile Water for Injection, USP. Sulfuric acid and/or sodium
hydroxide may have been added during manufacture to adjust the pH. †
Each vial contains tobramycin sulfate equivalent to 1200 mg of tobramycin. After
reconstitution, the solution will contain 40 mg of tobramycin per mL. The product
contains no preservative or sodium bisulfite.
Tobramycin sulfate is 0-3-amino-3-deoxy-a-D-glucopyranosyl-(1→4)-
0-[2,6-diamino-2,3,6-trideoxy-a-D-ribo-hexopyranosyl-(1→6)]-2-deoxy-
L-streptamine, sulfate (2:5)(salt) and has the chemical formula (C18H37N5O9)2•5H2SO4.
The molecular weight is 1425.45. The structural formula for tobramycin is as
follows:








The pharmacy bulk package of tobramycin for injection USP is a container of
a sterile preparation for parenteral use that contains multiple single doses.
It is intended for use in a pharmacy admixture program. Package use is restricted
to the preparation of admixures for intravenous infusion or to the filling of
empty sterile syringes for intravenous injections for patients with individualized
dosing requirements.
† Each vial contains tobramycin sulfate equivalent to
1200 mg of tobramycin.
Last reviewed on RxList: 11/13/2008




Tobramycin Injection Drug Description
Tobramycin
for Injection USP 1.2 gm†
This vial is intended for use by the hospital pharmacist in the extemporaneous
preparation of IV solutions.

PHARMACY BULK PACKAGE NOT FOR DIRECT INFUSION

To reduce the development of drug-resistant bacteria and maintain the effectiveness
of Tobramycin for Injection USP and other antibacterial drugs, tobramycin should
be used only to treat or prevent infections that are proven or strongly suspected
to be caused by bacteria.

WARNING
Patients treated with tobramycin for injection USP and other aminoglycosides
should be under close clinical observation, because these drugs have an inherent
potential for causing ototoxicity and nephrotoxicity. Neurotoxicity, manifested
as both auditory and vestibular ototoxicity, can occur. The auditory changes
are irreversible, are usually bilateral, and may be partial or total. Eighth-nerve
impairment and nephrotoxicity may develop, primarily in patients having preexisting
renal damage and in those with normal renal function to whom aminoglycosides
are administered for longer periods or in higher doses than those recommended.
Other manifestations of neurotoxicity may include numbness, skin tingling, muscle
twitching, and convulsions. The risk of aminoglycoside-induced hearing loss
increases with the degree of exposure to either high peak or high trough serum
concentrations. Patients who develop cochlear damage may not have symptoms during
therapy to warn them of eighth-nerve toxicity, and partial or total irreversible
bilateral deafness may continue to develop after the drug has been discontinued.
Rarely, nephrotoxicity may become apparent until the first few days after cessation
of therapy. Aminoglycoside-induced nephrotoxicity usually is reversible.
Renal and eighth-nerve function should be closely monitored in patients with
known or suspected renal impairment and also in those whose renal function is
initially normal but who develop signs of renal dysfunction during therapy.
Peak and trough serum concentrations of aminoglycosides should be monitored
periodically during therapy to assure adequate levels and to avoid potentially
toxic levels. Prolonged serum concentrations above 12 mcg/mL should be avoided.
Rising trough levels (above 2 mcg/mL) may indicate tissue accumulation. Such
accumulation, excessive peak concentrations, advanced age, and cumulative dose
may contribute to ototoxicity and nephrotoxicity (see PRECAUTIONS).
Urine should be examined for decreased specific gravity and increased excretion
of protein, cells, and casts. Blood urea nitrogen, serum creatinine, and creatinine
clearance should be measured periodically. When feasible, it is recommended
that serial audiograms be obtained in patients old enough to be tested, particularly
high-risk patients. Evidence of impairment of renal, vestibular, or auditory
function requires discontinuation of the drug or dosage adjustment.
Tobramycin for injection USP should be used with caution in premature and neonatal
infants because of their renal immaturity and the resulting prolongation of
serum half-life of the drug.
Concurrent and sequential use of other neurotoxic and/or nephrotoxic antibiotics,
particularly other aminoglycosides (eg. amikacin, streptomycin, neomycin, kanamycin,
gentamicin, and paromomycin), cephaloridine, viomycin, polymycin B, colistin,
cisplatin, and vancomycin, should be avoided. Other factors that may increase
patient risk are advanced age and dehydration.
Aminoglycosides should not be given concurrently with potent diuretics, such
as ethacrynic acid and furosemide. Some diuretics themselves cause ototoxicity,
and intravenously administered diuretics enhance aminoglycoside toxicity by
altering antibiotic concentrations in serum and tissue.
Aminoglycosides can cause fetal harm when administered to a pregnant woman
(see PRECAUTIONS).

DRUG DESCRIPTION
Tobramycin sulfate, a water-soluble antibiotic of the aminoglycoside group,
is derived from the actinomycete Streptomyces tenebrarius. Sterile tobramycin
sulfate is supplied as a sterile dry powder and is intended for reconstitution
with 30 mL of Sterile Water for Injection, USP. Sulfuric acid and/or sodium
hydroxide may have been added during manufacture to adjust the pH. †
Each vial contains tobramycin sulfate equivalent to 1200 mg of tobramycin. After
reconstitution, the solution will contain 40 mg of tobramycin per mL. The product
contains no preservative or sodium bisulfite.
Tobramycin sulfate is 0-3-amino-3-deoxy-a-D-glucopyranosyl-(1→4)-
0-[2,6-diamino-2,3,6-trideoxy-a-D-ribo-hexopyranosyl-(1→6)]-2-deoxy-
L-streptamine, sulfate (2:5)(salt) and has the chemical formula (C18H37N5O9)2•5H2SO4.
The molecular weight is 1425.45. The structural formula for tobramycin is as
follows:








The pharmacy bulk package of tobramycin for injection USP is a container of
a sterile preparation for parenteral use that contains multiple single doses.
It is intended for use in a pharmacy admixture program. Package use is restricted
to the preparation of admixures for intravenous infusion or to the filling of
empty sterile syringes for intravenous injections for patients with individualized
dosing requirements.
† Each vial contains tobramycin sulfate equivalent to
1200 mg of tobramycin.
Last reviewed on RxList: 11/13/2008




Tobramycin Injection Drug Description
Tobramycin
for Injection USP 1.2 gm†
This vial is intended for use by the hospital pharmacist in the extemporaneous
preparation of IV solutions.

PHARMACY BULK PACKAGE NOT FOR DIRECT INFUSION

To reduce the development of drug-resistant bacteria and maintain the effectiveness
of Tobramycin for Injection USP and other antibacterial drugs, tobramycin should
be used only to treat or prevent infections that are proven or strongly suspected
to be caused by bacteria.

WARNING
Patients treated with tobramycin for injection USP and other aminoglycosides
should be under close clinical observation, because these drugs have an inherent
potential for causing ototoxicity and nephrotoxicity. Neurotoxicity, manifested
as both auditory and vestibular ototoxicity, can occur. The auditory changes
are irreversible, are usually bilateral, and may be partial or total. Eighth-nerve
impairment and nephrotoxicity may develop, primarily in patients having preexisting
renal damage and in those with normal renal function to whom aminoglycosides
are administered for longer periods or in higher doses than those recommended.
Other manifestations of neurotoxicity may include numbness, skin tingling, muscle
twitching, and convulsions. The risk of aminoglycoside-induced hearing loss
increases with the degree of exposure to either high peak or high trough serum
concentrations. Patients who develop cochlear damage may not have symptoms during
therapy to warn them of eighth-nerve toxicity, and partial or total irreversible
bilateral deafness may continue to develop after the drug has been discontinued.
Rarely, nephrotoxicity may become apparent until the first few days after cessation
of therapy. Aminoglycoside-induced nephrotoxicity usually is reversible.
Renal and eighth-nerve function should be closely monitored in patients with
known or suspected renal impairment and also in those whose renal function is
initially normal but who develop signs of renal dysfunction during therapy.
Peak and trough serum concentrations of aminoglycosides should be monitored
periodically during therapy to assure adequate levels and to avoid potentially
toxic levels. Prolonged serum concentrations above 12 mcg/mL should be avoided.
Rising trough levels (above 2 mcg/mL) may indicate tissue accumulation. Such
accumulation, excessive peak concentrations, advanced age, and cumulative dose
may contribute to ototoxicity and nephrotoxicity (see PRECAUTIONS).
Urine should be examined for decreased specific gravity and increased excretion
of protein, cells, and casts. Blood urea nitrogen, serum creatinine, and creatinine
clearance should be measured periodically. When feasible, it is recommended
that serial audiograms be obtained in patients old enough to be tested, particularly
high-risk patients. Evidence of impairment of renal, vestibular, or auditory
function requires discontinuation of the drug or dosage adjustment.
Tobramycin for injection USP should be used with caution in premature and neonatal
infants because of their renal immaturity and the resulting prolongation of
serum half-life of the drug.
Concurrent and sequential use of other neurotoxic and/or nephrotoxic antibiotics,
particularly other aminoglycosides (eg. amikacin, streptomycin, neomycin, kanamycin,
gentamicin, and paromomycin), cephaloridine, viomycin, polymycin B, colistin,
cisplatin, and vancomycin, should be avoided. Other factors that may increase
patient risk are advanced age and dehydration.
Aminoglycosides should not be given concurrently with potent diuretics, such
as ethacrynic acid and furosemide. Some diuretics themselves cause ototoxicity,
and intravenously administered diuretics enhance aminoglycoside toxicity by
altering antibiotic concentrations in serum and tissue.
Aminoglycosides can cause fetal harm when administered to a pregnant woman
(see PRECAUTIONS).

DRUG DESCRIPTION
Tobramycin sulfate, a water-soluble antibiotic of the aminoglycoside group,
is derived from the actinomycete Streptomyces tenebrarius. Sterile tobramycin
sulfate is supplied as a sterile dry powder and is intended for reconstitution
with 30 mL of Sterile Water for Injection, USP. Sulfuric acid and/or sodium
hydroxide may have been added during manufacture to adjust the pH. †
Each vial contains tobramycin sulfate equivalent to 1200 mg of tobramycin. After
reconstitution, the solution will contain 40 mg of tobramycin per mL. The product
contains no preservative or sodium bisulfite.
Tobramycin sulfate is 0-3-amino-3-deoxy-a-D-glucopyranosyl-(1→4)-
0-[2,6-diamino-2,3,6-trideoxy-a-D-ribo-hexopyranosyl-(1→6)]-2-deoxy-
L-streptamine, sulfate (2:5)(salt) and has the chemical formula (C18H37N5O9)2•5H2SO4.
The molecular weight is 1425.45. The structural formula for tobramycin is as
follows:








The pharmacy bulk package of tobramycin for injection USP is a container of
a sterile preparation for parenteral use that contains multiple single doses.
It is intended for use in a pharmacy admixture program. Package use is restricted
to the preparation of admixures for intravenous infusion or to the filling of
empty sterile syringes for intravenous injections for patients with individualized
dosing requirements.
† Each vial contains tobramycin sulfate equivalent to
1200 mg of tobramycin.
Last reviewed on RxList: 11/13/2008




Tobramycin Injection Drug Description
Tobramycin
for Injection USP 1.2 gm†
This vial is intended for use by the hospital pharmacist in the extemporaneous
preparation of IV solutions.

PHARMACY BULK PACKAGE NOT FOR DIRECT INFUSION

To reduce the development of drug-resistant bacteria and maintain the effectiveness
of Tobramycin for Injection USP and other antibacterial drugs, tobramycin should
be used only to treat or prevent infections that are proven or strongly suspected
to be caused by bacteria.

WARNING
Patients treated with tobramycin for injection USP and other aminoglycosides
should be under close clinical observation, because these drugs have an inherent
potential for causing ototoxicity and nephrotoxicity. Neurotoxicity, manifested
as both auditory and vestibular ototoxicity, can occur. The auditory changes
are irreversible, are usually bilateral, and may be partial or total. Eighth-nerve
impairment and nephrotoxicity may develop, primarily in patients having preexisting
renal damage and in those with normal renal function to whom aminoglycosides
are administered for longer periods or in higher doses than those recommended.
Other manifestations of neurotoxicity may include numbness, skin tingling, muscle
twitching, and convulsions. The risk of aminoglycoside-induced hearing loss
increases with the degree of exposure to either high peak or high trough serum
concentrations. Patients who develop cochlear damage may not have symptoms during
therapy to warn them of eighth-nerve toxicity, and partial or total irreversible
bilateral deafness may continue to develop after the drug has been discontinued.
Rarely, nephrotoxicity may become apparent until the first few days after cessation
of therapy. Aminoglycoside-induced nephrotoxicity usually is reversible.
Renal and eighth-nerve function should be closely monitored in patients with
known or suspected renal impairment and also in those whose renal function is
initially normal but who develop signs of renal dysfunction during therapy.
Peak and trough serum concentrations of aminoglycosides should be monitored
periodically during therapy to assure adequate levels and to avoid potentially
toxic levels. Prolonged serum concentrations above 12 mcg/mL should be avoided.
Rising trough levels (above 2 mcg/mL) may indicate tissue accumulation. Such
accumulation, excessive peak concentrations, advanced age, and cumulative dose
may contribute to ototoxicity and nephrotoxicity (see PRECAUTIONS).
Urine should be examined for decreased specific gravity and increased excretion
of protein, cells, and casts. Blood urea nitrogen, serum creatinine, and creatinine
clearance should be measured periodically. When feasible, it is recommended
that serial audiograms be obtained in patients old enough to be tested, particularly
high-risk patients. Evidence of impairment of renal, vestibular, or auditory
function requires discontinuation of the drug or dosage adjustment.
Tobramycin for injection USP should be used with caution in premature and neonatal
infants because of their renal immaturity and the resulting prolongation of
serum half-life of the drug.
Concurrent and sequential use of other neurotoxic and/or nephrotoxic antibiotics,
particularly other aminoglycosides (eg. amikacin, streptomycin, neomycin, kanamycin,
gentamicin, and paromomycin), cephaloridine, viomycin, polymycin B, colistin,
cisplatin, and vancomycin, should be avoided. Other factors that may increase
patient risk are advanced age and dehydration.
Aminoglycosides should not be given concurrently with potent diuretics, such
as ethacrynic acid and furosemide. Some diuretics themselves cause ototoxicity,
and intravenously administered diuretics enhance aminoglycoside toxicity by
altering antibiotic concentrations in serum and tissue.
Aminoglycosides can cause fetal harm when administered to a pregnant woman
(see PRECAUTIONS).

DRUG DESCRIPTION
Tobramycin sulfate, a water-soluble antibiotic of the aminoglycoside group,
is derived from the actinomycete Streptomyces tenebrarius. Sterile tobramycin
sulfate is supplied as a sterile dry powder and is intended for reconstitution
with 30 mL of Sterile Water for Injection, USP. Sulfuric acid and/or sodium
hydroxide may have been added during manufacture to adjust the pH. †
Each vial contains tobramycin sulfate equivalent to 1200 mg of tobramycin. After
reconstitution, the solution will contain 40 mg of tobramycin per mL. The product
contains no preservative or sodium bisulfite.
Tobramycin sulfate is 0-3-amino-3-deoxy-a-D-glucopyranosyl-(1→4)-
0-[2,6-diamino-2,3,6-trideoxy-a-D-ribo-hexopyranosyl-(1→6)]-2-deoxy-
L-streptamine, sulfate (2:5)(salt) and has the chemical formula (C18H37N5O9)2•5H2SO4.
The molecular weight is 1425.45. The structural formula for tobramycin is as
follows:








The pharmacy bulk package of tobramycin for injection USP is a container of
a sterile preparation for parenteral use that contains multiple single doses.
It is intended for use in a pharmacy admixture program. Package use is restricted
to the preparation of admixures for intravenous infusion or to the filling of
empty sterile syringes for intravenous injections for patients with individualized
dosing requirements.
† Each vial contains tobramycin sulfate equivalent to
1200 mg of tobramycin.
Last reviewed on RxList: 11/13/2008





Other reviews about Tobramycin on wordpress

Cystic Fibrosis Axentis Pharma Initiates Clinical Trial For Lung Infections
  by salimshaikh
Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection […]


A little better
  by everydayisprecious
Marcy seemed a little better yesterday, not needing as much suctioning last night and not asking for Benadryl last night or Valium this morning. Kara was here yesterday. I […]


Speciation in, abx started
  by everydayisprecious
Marcy still felt bad yesterday. Her sputum culture is growing a Pseudomonas Aeruginosa (again) that is sensitive to 4 antibiotics including 3 that we still have here at […]


Long Overdue!!
  by A's Mommy
Wow it has been a long time since I have blogged!!! A is back to himself and has been for about a week now. He came off the […]


Recovery cont.
  by lschwieters
I had a quiet day at home.  The home health nurse came to draw blood today.  The rule is that you can't dose the Tobramycin until the nurse […]


Drug Information Requests
  by JennD
1) Pharmaceutical Care “Is statin therapy recommended for all post-stroke patients?” “Is ranitidine therapy recommended for a patient receiving chronic warfarin and prednisone therapy?” “Does Varenicline interact with HIV medications?” 2) CTU "Can […]


June/July...and Today...My Due Date
  by A's Mommy
Wow I am really slacking here with the blog. And as I keep up to date with others I am feeling really guilty. I used to be so […]


Tobramycin
  by carladumes
I successfully did an aminoglycoside interpretation on my rotation! :) It actually involved much more work than just looking at the levels. It turns out many of the times […]


Allergen of the Year for 2010 Announced
  by meddyblogger
from the American Contact Dermatitis Society annual meeting, Miami Beach Drum roll please ... the American Contact Dermatitis Society has named the antibiotic neomycin as Allergen of the Year […]


IV time again . . . Day 4
  by cfjourney
I guess I should be thankful as I've been off IVs for 5 months! My hubby and I both started with a cold last Tuesday - and OH BOY […]



Other reviews about Tobramycin on web:

Tobramycin sulfate is an aminoglycoside antibiotic used to treat various types of bacterial infections, particularly Gram-negative infections. Tobramycin - Wikipedia, the free encyclopedia


Accurate, FDA approved Tobramycin information for healthcare professionals and patients - brought to you by Drugs.com. Tobramycin Official FDA information, side effects and uses.


Tobramycin Brand names: AK-Tob®Nebcin®Tobi®Tobrex® Chemical formula: Drug Forms: Tobramycin Sulfate Solution for injection (below) Tobramycin: Definition from Answers.com


All about Tobramycin. View complete and up to date Tobramycin information - part of the Drugs.com trusted medication database. Tobramycin Facts and Comparisons at Drugs.com


tobramycin /to·bra·my·cin/ (to″brah-mi´sin) an aminoglycoside antibiotic derived from a complex produced by Streptomyces tenebrarius, bactericidal against many gram-negative and ... tobramycin - definition of tobramycin in the Medical dictionary ...


Learn about the prescription medication Tobramycin Injection (Tobramycin Injection), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Tobramycin Injection (Tobramycin Injection) Drug Information: Uses ...


Mayo Clinic offers award-winning medical and health information and tools for healthy living. Tobramycin (Ophthalmic Route) - MayoClinic.com


Consumer information about the medication TOBRAMYCIN - INJECTION (Nebcin), includes side effects, drug interactions, recommended dosages, and storage information. Read more ... TOBRAMYCIN - INJECTION (Nebcin) side effects, medical uses, and ...


Learn about the prescription medication Tobradex (Tobramycin and Dexamethasone), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Tobradex (Tobramycin and Dexamethasone) Drug Information: Uses ...


–noun Pharmacology. a highly toxic aminoglycoside antibiotic, C 18 H 37 N 5 O 9, derived from Streptomyces tenebarius, used in the treatment of serious infections due to susceptible Gram ... Tobramycin | Define Tobramycin at Dictionary.com





Featured Reviews

Reviews Methyldopate Hcl

Methyldopate Hcl Drug Description Methyldopate Hcl (methyldopate hydrochloride) Injection, Solution DRUG DESCRIPTION Methyldopate HCl Injection, USP, is an antihypertensive agent for intravenous use. Sterile, nonpyrogenic. Methyldopate...
Read More  |  Review This
Reviews Motrin

Motrin Drug Description MOTRIN® (ibuprofen) Tablets, USP Cardiovascular Risk NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk...
Read More  |  Review This
Reviews Influenza Virus Vaccine

FluMist Drug Description FluMist® (influenza virus vaccine live) Intranasal DRUG DESCRIPTION What are the possible side effects of influenza virus nasal vaccine (FluMist)? Nasal influenza virus (live virus) vaccine may cause...
Read More  |  Review This
Reviews SecreFlo

SecreFlo Drug Description SecreFlo™ (secretin) for Injection DRUG DESCRIPTION SecreFlo™ (secretin) is a pure sterile, nonpyrogenic, lyophilized white cake powder acetate salt of secretin, a peptide hormone. Secretin has an...
Read More  |  Review This
Reviews Calciferol

Calciferol Drug Description VITAMIN D ERGOCALCIFEROL Capsules, USP 1.25 mg SOFTGELS (Soft Gelatin Capsules) (50,000 USP Units) DRUG DESCRIPTION What are the possible side effects of ergocalciferol (Calciferol, Drisdol, Vitamin...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....